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INTRODUCTION
Keratoconus is generally a progressive, bilateral cone-like ectasia 
of the cornea that affects approximately 1 in 2,000 people in the gene-
ral population, which is usually diagnosed in young adult patients(1). It 
is characterized by localized corneal thinning and protrusion, which 
lead to high myopia and irregular astigmatism that reduces visual 
quality. The initial treatment of keratoconus is the use of glasses and/
or contact lenses(1). More advanced stages of the disease are treated 
by various surgical procedures(2). However, the relief of keratoconus 
symptoms using currently available treatment modalities may not be 
permanent, and it remains impossible to predict with certainty how 
long favorable results will persist.
The pathophysiology of keratoconus remains poorly defined, 
but its etiology is known to be multifactorial and it is an autosomal 
dominant trait with variable phenotypic expression(2). It is associated 
with many ophthalmic and systemic conditions, such as Down syn-
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ABSTRACT
Purpose: To evaluate whether reducing eyelid muscular force through the administra-
tion of botulinum toxin type A (BTX-A) to the orbicularis oculi muscles of patients 
with keratoconus affected corneal parameters indicative of disease progression. 
Methods: In this prospective parallel randomized clinical trial, 40 eyes of 40 patients 
with keratoconus were randomized into equally sized control and BTX-A groups. 
Patients in the BTX-A group received subcutaneous BTX-A injections into the 
orbicularis muscle. The control group received no intervention. Palpebral fissure 
height, best spectacle-corrected visual acuity (BSCVA), and corneal topographic 
parameters were evaluated at baseline and at 3-, 6-, 12-, and 18-month follow-ups. 
Results: The mean ± standard deviation vertical palpebral fissure heights were 
9.74 ± 1.87 mm and 9.45 ± 1.47 mm at baseline in the control and BTX-A groups, 
respectively, and 10.0 ± 1.49 mm and 9.62 ± 1.73 mm at 18 months, with no sig-
nificant difference between the groups (p=0.337). BSCVA values were 0.63 ± 0.56 
and 0.60 ± 0.27 at baseline in the control and BTX-A groups (p=0.643), and 0.52 ± 
0.59 and 0.45 ± 0.26 at 18 months, again with no significant difference between 
the groups (p=0.452). In addition, there were no statistical differences between the 
groups at 18 months for the three keratometry topographic parameters: flattest 
(K1), steepest (K2), and mean (Km) keratometry (p=0.562). 
Conclusion: BTX-A inhibition of eyelid force generation did not result in detec-
table changes in corneal parameters in keratoconic patients during 18 months 
of follow-up.
Keywords: Corneal diseases; Keratoconus; eyelids; Botulinum toxins/therapeutic 
use
RESUMO
Objetivo: Avaliar se a administração da toxina botulínica tipo A (BTX-A) no músculo 
orbicular de pacientes com ceratocone a fim de reduzir a força muscular palpebral 
pode alterar os parâmetros corneanos indicativos de progressão da doença.
Métodos: Ensaio clínico randomizado paralelo prospectivo. Quarenta olhos de 40 
pacientes, randomizados em grupo controle ou grupo BTX-A na razão de 1:1. Pa-
cientes do grupo BTX-A foram submetidos à injeção subcutânea da toxina botulínica 
tipo A no músculo orbicular. Os pacientes do grupo controle não sofreram nenhuma 
intervenção. Foram avaliados a medida da fenda palpebral, melhor acuidade visual 
corrigida, e topografia corneana nos momentos pré-operatório, e aos 3-,6-,12-, e 18 
meses de seguimento. 
Resultados: Média ± DP (desvio padrão) da fenda palpebral no pré-operatório nos 
grupos controle e BTX-A foram 9,74 ± 187 e 9,45 ± 1,47 mm, respectivamente; aos 
18 meses, a média da altura da fenda palpebral vertical nos grupos controle e BTX-A 
foram 10,0 ± 1,49 mm e 9,62 ± 1,73 mm, respectivamente, sem diferença significante 
entre os grupos (p=0,337). A média pré-operatória da melhor acuidade visual corri-
gida nos grupos controle e BTX-A foram 0,63 ± 0,56 e 0,60 ± 0,27, respectivamente 
(p=0,643); aos 18 meses, a média nos grupos controle e BTX-A foram 0,52 ± 0,59 e 
0,45 ± 0,26, respectivamente, sem diferença significante entre os grupos (p=0,452). 
Não houve diferença estatística entre os grupos aos 18 meses para todos os parâ-
metros topográficos ceratométricos avaliados, mais plano-(K1), mais curvo-(K2), e 
ceratometria média Km (p≥0,562). 
Conclusão: A inibição da força muscular palpebral pela toxina botulínica tipo A 
não causou alterações detectáveis nos parâmetros corneanos em pacientes com 
ceratocone, com 18 meses de seguimento.
Descritores: Doenças da córnea; Ceratocone; Pálpebras; Toxinas botulínicas/uso te -
ra pêutico
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drome, eye rubbing, mitral valve prolapse, collagen vascular disease, 
and a history of contact lens wear(2). Other conditions include eyelid 
diseases such as blepharoptosis(3) and floppy eyelid syndrome(4). 
Keratoconus patients present with excessive eye blinking, and 
usually develop a routine of chronic eye rubbing with consequent 
excessive manipulation of the periocular area. Augmented pressure 
to the eyelids may cause further topographic changes to the cor-
nea(5,6), and eyelid muscular force can translate to the ocular surface 
and exacerbate symptoms. It was therefore hypothesized that redu-
cing eyelid muscular force may provide a novel treatment option for 
keratoconus that inhibited the progression of damage to the cornea.
The use of botulinum toxin type A (BTX-A) in medicine was first 
reported in 1980 for treating strabismus(7). It blocks the release of 
acetylcholine into the neuromuscular junction, leading to temporary 
muscle weakness or paralysis(8). BTX-A is now a front-line treatment 
option for focal dystonias such as essential blepharospasm and he-
mifacial spasm, and it has become a major therapeutic drug with va-
luable applications in diverse medical subspecialties(8). The purpose 
of this study was to evaluate, as a potential novel therapy for patients 
with keratoconus, whether reducing eyelid muscular force through 
the administration of BTX-A into the orbicularis oculi muscles could 
prevent the progression of corneal damage. 
METHODS
DESign
This parallel randomized clinical trial was conducted between 
September 2012 and October 2014 in the Department of Ophthal-
mology and Visual Sciences, Federal University of São Paulo, Brazil. 
The study was approved by the Institutional Ethics Committee and 
followed the tenets of the Declaration of Helsinki. All patients provi-
ded written informed consent. This manuscript has been registered 
(NCT01691651) and is publicly available at www.clinicaltrials.gov.
ParTiciPanTS
Patients were enrolled if they met the following inclusion criteria: 
documented keratoconus, best spectacle-corrected visual acuity 
(BSCVA) that could be measured by refraction, no major comorbi-
dities such as diabetes, and aged 10-40 years. Exclusion criteria were 
having only one functional eye, previous ocular surgery, eyelid 
margin disease that did not respond to treatment (e.g., meibomian 
gland dysfunction and blepharitis), a known allergy to BTX-A or other 
medication components, a history of herpetic keratitis, concurrent 
corneal infection, pregnancy or nursing, and other ocular diseases 
that could affect visual acuity.
SaMPlE SizE anD ranDOMizaTiOn
The two main outcomes considered in this study were the dimen-
sions of the palpebral fissure and keratometry measurements; the 
sample size was calculated on the basis of these. From a pilot study 
per formed in our department, we expected a mean ± standard devia-
tion (SD) change in the height of the palpebral fissure of 2.0 ± 1.5 mm 
and an astigmatism change of 1.0 ± 0.8 diopters (D). We calculated that 
a sample size of 20 individuals/group would provide 90% power to de-
tect these magnitudes of outcome differences in the present study.
Randomization was performed using a computer-generated ran-
domization table (Stata v.11, Stata Corp, College Station, TX). The par -
ticipants were allocated into either the control or the BTX-A injection 
group in a 1:1 ratio. Due to the design of this study (treatment versus 
no treatment), the examiner was not masked to the type of treatment 
during examination, although the statistician was masked during 
data analysis. 
MEaSurES
At the baseline and post-treatment follow-up examinations at 
3, 6, 12, and 18 months, all participants underwent the following 
assessments: 1) uncorrected visual acuity (UCVA); 2) BSCVA; 3) mani-
fest refraction in a bright environment; 4) slit-lamp biomicroscopy; 
5) measurement of the palpebral fissure using ImageJ software 
(v.1.46s, National Institutes of Health, Bethesda, MD, USA); 6) corneal 
topography and tomography (Allegro Oculyzer®, Alcon Laboratories, 
Fort Worth, TX, USA) and Pentacam® optical topography assessment 
(Oculus Optikgerate GmbH, Wetzlar, Germany); 7) Goldmann appla-
nation tonometry (GAT; Haag-Streit, Konig, Switzerland); and 8) ocular 
fundus examination. All evaluations were performed by the same 
examiner (ACR).
MEaSurEMEnT Of THE PalPEbral fiSSurE 
ImageJ is a public domain Java image processing program that 
can display, edit, analyze, process, save, and print images. It can also 
calculate the area and pixel value statistics of user-defined selections, 
measure distances and angles, and create density histograms and 
line profile plots.
An eyelid examination was performed with the eye image regis-
tration of patients in the primary position of gaze with a portable 
Sony® Cyber-shot digital camera attached to a monopod. To ensure 
the standardization of all measurements, photographs were taken 
with the participant positioned on a chin rest (for a slit-lamp) with 
a ruler attached at the forehead support. The same slit-lamp was 
used in all evaluations, thereby maintaining the same distance from 
the digital camera to the chin rest. The palpebral fissure height was 
drawn as a vertical line from the upper to the lower eyelid margin, 
passing through the pupil. Multiple images were captured from the 
study eye, and the mean measurement from the selected images 
was calculated.
injEcTiOn Of bOTulinuM TOxin TyPE a
Patients in the BTX-A injection group were treated with an in-
jection of onabotulinumtoxinA (Botox®, Allergan, Irvine, CA, USA) to 
the palpebral portion of the orbicularis oculi muscle. Reconstitution 
of the drug and its application were performed by a single investi-
gator (MHO) according to a standardized protocol. Immediately 
be fore appli cation, each vial was reconstituted with normal saline 
without preservatives to a final BTX-A concentration of 50 U/mL. The 
participant was seated and received a total of 12.0 U of BTX-A per 
application, injected using an insulin syringe in equal doses into the 
palpebral portion of the orbicularis oculi muscle of the upper and 
lower eyelids. BTX-A was applied twice: after the baseline measure-
ments, and then six months after the first injection. 
STaTiSTical analySiS
The intention-to-treat principle was used in the analysis. Pre- and 
post-treatment analyses were conducted using the Wilcoxon signed-
rank test. Between-group analyses used the Mann-Whitney U-test for 
continuous variables and Fisher’s exact test for categorical variables 
measured at each follow-up visit. All analyses were performed using 
Stata v.11 software, and p-values <0.05 were considered statistically 
significant. Data are presented as mean ± SD unless otherwise noted.
RESULTS
A total of 40 individuals (40 eyes) were enrolled at baseline. Three 
participants were lost due to voluntary non-participation in some 
of the follow-up visits, and so only 37 eyes of 37 participants were 
included for some of the follow-up analyses. 
All of the eyes were graded according to the Amsler-Krumeich 
classification(9), based on each participant’s refraction, mean central 
K-reading, corneal signs, and corneal thickness. Eyes were graded 
stage I, II, or III according to this classification. 
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ParTiciPanT DEMOgraPHicS
Participant demographics, study eye laterality, baseline palpebral 
height, corneal topography, and spherical equivalent (SE) were simi-
lar between the two study groups (Table 1).
ViSual acuiTy
Both UCVA and BSCVA, measured using a logMAR chart, were 
similar between the two study groups at baseline and at all follow-up 
time points (Figure 1). 
rEfracTiVE rESulTS
The mean baseline SE was -9.23 ± 6.03 D in the control group 
and -8.97 ± 6.12 D in the BTX-A group (p=0.870; Tables 1 and 2). At 18 
months, the mean SE was -9.70 ± 6.20 D in the control group and -8.66 
± 5.14 D in the BTX-A group, with no statistically significant difference 
between the groups (p=0.583; Table 2).
TOPOgraPHic rESulTS
After adjusting for baseline levels, there was no statistically signi-
ficant difference between the groups at the 18-month follow-up for 
all three topography parameters assessed with the Pentacam® (flat-
test keratometry (K1), p=0.795; steepest keratometry (K2), p=0.562; 
and mean keratometry (Km), p=0.903), and with the Oculyzer® (K1, 
p=0.783; K2, p=0.783; and Km, p=0.842) (Figure 2).
PalPEbral fiSSurE
The mean height of the palpebral fissure at baseline was 9.74 ± 
1.87 mm in the control group and 9.45 ± 1.47 mm in the BTX-A group 
(p=0.560; Tables 1 and 3). At 18 months, the respective palpebral fissure 
measurements were similar at 10.0 ± 1.49 mm and 9.62 ± 1.73 mm 
in the control and BTX-A groups, respectively (p=0.337; Table 3). 
PacHyMETry rESulTS
Table 4 shows the pachymetry results at the central and thinnest 
parts of the corneas. There was no statistically significant difference 
between the two study groups at 18 months of follow-up in any 
parameter (p=0.669 and p=0.464 for the central and thinnest cor-
neal regions measured by Pentacam® pachymetry, and p=0.748 and 
p=0.502 for the central and thinnest areas measured by Oculyzer® 
pachymetry).
TOnOMETry rESulTS
The tonometry data were evaluated by GAT. Intraocular pressure 
(IOP) did not differ significantly between the groups at 18 months 
(p=0.322; Table 5).
cOMPlicaTiOnS
No participant in the BTX-A group presented early or late compli-
cations following the BTX-A applications, including lagophthalmos, 
diplopia, or blepharoptosis. 
DISCUSSION
Various factors can result in the deterioration of keratoconus, in -
cluding ultraviolet-B light, atopy, mechanical eye rubbing, and im-
properly fitting contact lenses(2). Researchers have studied genetic, 
histopathologic, biomechanical, and inflammatory aspects of the 
disease to elucidate keratoconus etiology and improve the currently 
available treatments(10,11). Elevated tension within the eyelid can be 
transmitted to the juxtaposed corneal surface, thereby altering the 
corneal topography(5,12); thus, reducing the muscular force of the eye-
lid may result in changes to corneal measurements in keratoconus 
patients. With the goal of developing new treatment options for ke-
ratoconus, the present study evaluated whether BTX-A injection into 
Table 1. Comparison of baseline characteristics between the botuli-
num toxin-A injection and control groups
Parametera Control (n=21) BTX-A (n=19) P-value
Age, years -25.95 (07.33) -21.31 (07.60) 0.052
Sex, n (%) 0.087
Female -11.00 (52.40) -05.00 (26.40)
Male -10.00 (47.60) 14.00 (73.60)
Eye, n (%) 0.357
Right -11.00 (52.40) -12.00 (63.10)
Left -10.00 (47.60) -07.00 (36.90)
Palpebral fissure, mm -09.74 (01.87) -09.45 (01.47) 0.560
Steepest K, Pentacam, D -53.09 (07.29) -53.41 (05.44) 0.714
Flattest K, Pentacam, D -49.41 (05.69) -48.23 (05.19) 0.645
Mean K, Pentacam, D -51.17 (06.38) -50.67 (05.21) 0.989
Steepest K, Oculyzer, D -53.16 (07.24) -53.53 (05.04) 0.694
Flattest K, Oculyzer, D -49.86 (05.88) -48.40 (05.28) 0.606
Mean K, Oculyzer, D -51.45 (06.45) 50.80 (05.11) 0.989
Spherical equivalent, D 0-9.23 (06.03) 0-8.97 (06.12) 0.870
a= values shown are mean (standard deviation), unless noted as “n (%).”  BTX-A= botuli-
num toxin-A; K= keratometry measurements made with a pentacam® or Oculyzer® de vice; 
D= diopters.
Figure 1. Uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA) on 
a logMAR chart.
Table 2. Comparison of the spherical equivalent measurements between the botulinum toxin-A injection and control groups
Parameter, mean (SD) Baseline 3 months 6 months 12 months 18 months
Spherical equivalent, D
Control -9.23 (6.03) -9.51 (6.03) -9.60 (6.13) -9.80 (6.17) -9.70 (6.20)
BTX-A -8.97 (6.12) -8.94 (5.90) -8.85 (5.89) -8.71 (5.70) -8.66 (5.14)
P-value 0.870 0.796  0.663 0.564 0.583
SD= standard deviation; D= diopters; BTX-A= botulinum toxin-A.
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BTX-A= botulinum toxin-A.
Figure 2. Topographic corneal indexes (steepest, mean, and flattest keratometry) by 
Pentacam® and Oculyzer® in the control and botulinum toxin-A injection groups. 
Table 3. Comparison of the heights of the palpebral fissure between the botulinum toxin-A injection and control groups
Parameter, mean (SD) Baseline 3 months 6 months 12 months 18 months
Palpebral fissure, mm
Control 9.74 (1.87) 9.14 (1.26) 9.84 (1.19) 9.66 (1.75) 10.06 (1.49)
BTX-A 9.45 (1.47) 9.79 (1.28) 9.82 (1.51) 9.84 (1.59) 0 9.62 (1.73)
SD= standard deviation; BTX-A= botulinum toxin A.
the orbicularis oculi muscles of keratoconus patients improved cor-
neal topographic parameters by reducing the eyelid muscular forces 
that are translated to the ocular surface and exacerbate symptoms.
However, the administration of two BTX-A doses over 6 months 
resulted in no changes to visual acuity and refraction in our kerato-
conus cohort. Previous studies have reported no success in treating 
keratoconus by cross-linking corneal collagen matrices to stabilize 
the ocular tissue(13,14), an approach that also brought no changes in 
UCVA, BSCVA, SE, or keratometry. Another keratoconus intervention 
involves implanting plastic intracorneal ring segments to stabilize 
the cornea, but this brings the risk of ocular complication, requiring 
ca reful selection of patients appropriate for the procedure(2,15,16). Se-
veral factors contribute to the development of corneal astigmatism, 
including age, sex, tear film insufficiency, IOP, and physical pressure 
exerted by the eyelids(17). In a 2015 report by members of our research 
team, the magnitude of astigmatism was significantly reduced and 
palpebral fissure height significantly increased in the affected eyes 
of hemifacial spasm patients treated with BTX-A(18). In that study, 
BTX-A treatment temporally alleviated eyelid tension, thereby poten-
tially reducing the transmission of physical forces from the eyelids to 
the cornea. In the present study, no statistically significant differences 
were observed in the corneal topographic parameters and palpebral 
fissure dimensions of keratoconus eyes during the 18 months following 
BTX-A administration. Usually, BTX-A effects appear within 1-2 days, 
peak at 1-2 weeks, and gradually decline after 3-6 months, depending 
on the patient’s clinical condition(8). We observed no differences in 
palpebral fissure measurements 3 months after the first and second 
BTX-A applications, probably because the tension exerted by the eyelid 
on the cornea in keratoconus patients is not as high as it is in hemifacial 
spasm patients. Thus, BTX-A application to the orbicularis oculi muscles 
of keratoconus patients was not associated with significant changes in 
corneal astigmatism or palpebral fissure dimensions.
Methodologies for evaluating eyelid tension are not standardized 
and vary between studies, complicating the comparison of results 
Table 4. Comparison between the botulinum toxin-A injection and control groups of corneal pachymetric measurements made using the Penta-
cam® and Oculyzer® devices
Parameter, mean (SD) Baseline 3 months 6 months 12 months 18 months
Pentacam®
Central position, µm
Control 447.7 (47.6) 451.4 (42.7) 451.0 (50.3) 445.1 (46.4) 447.0 (47.9)
BTX-A 460.4 (45.7) 447.1 (48.7) 464.1(45.0) 453.4 (60.0) 454.7 (53.9)
Thinnest position, µm
Control 419.6 (53.0) 421.8 (44.2) 423.5 (55.9) 416.0 (51.1) 418.5 (52.2)
BTX-A 433.1 (46.9) 430.0 (48.9) 437.8 (45.6) 431.1 (57.3) 425.6 (52.4)
Oculyzer®
Central position, µm
Control 461.9 (46.4) 464.4 (46.8) 464.0 (50.0) 459.7 (52.5) 463.4 (47.8)
BTX-A 469.6 (49.1) 473.9 (53.8) 471.4 (59.3) 466.3 (66.1) 459.5 (63.4)
Thinnest position, µm
Control 430.7 (55.1) 430.7 (54.4) 432.4 (52.6) 430.7 (54.7) 433.6 (49.8)
BTX-A 439.8 (51.9) 443.6 (52.4) 442.4 (53.7) 432.6 (67.6) 432.5 (63.1)
SD= standard deviation; BTX-A= botulinum toxin-A.
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from different groups. The present study indirectly evaluated the re-
duction in eyelid muscular force due to BTX-A application to the orbi-
cularis oculi muscles by studying the subsequent effects on the corneal 
topographic parameters. Other research groups have described using 
a lid tensiometer instrument to assess the generation of eyelid muscu-
lar force(19,20). One report indicated that, under normal circumstances, 
eyelid tension was unlikely to adversely affect the shape and power of 
the cornea(19). In addition, it has been noted that no difference in lid 
tension exists between Asians and Caucasians(20) even though Asians 
are at increased predisposition to developing keratoconus. In contrast, 
studies that evaluated corneal astigmatism changes after BTX-A injec-
tion in patients with blepharospasm concluded that eyelid-derived 
forces may play an important role in modifying corneal curvature(17,21). 
The pachymetry results for the central and thinnest regions of 
the cornea remained similar between the groups throughout the 18 
months of follow-up. This is not surprising, because we did not admi-
nister BTX-A directly into the corneal tissue. Pachymetry was assessed 
using two different devices, but both were based on the same principle 
(Scheimpflug tomography). This approach has good reproducibility 
in differentiating normal corneas from subclinical and symptomatic 
keratoconus cases(22).
GAT is the gold standard for tonometry and is the most frequently 
used technique for IOP measurement. Eyes with corneal pathologies 
can present challenges for measuring IOP because of changes to the 
corneal thickness, rigidity, and curvature(23). However, newer tonome-
ters such as the Pascal dynamic contour tonometer (Ziemer Ophthal-
mic Systems AG, Bern, Switzerland) and the Ocular Response Analyzer 
and TonoPen XL (Reichert Ophthalmic Instruments, Depew, NY, USA) 
have better diagnostic accuracy than GAT for keratoconic corneas(23).
We are not aware of any previous reports that have used BTX-A to 
reduce eyelid muscular force in patients with keratoconus. Although 
several studies(17-20) have confirmed the influence of eyelid tension on 
corneal shape, it appears that eyelid tension in keratoconus patients 
is no higher than for other conditions such as hemifacial spasm and 
blepharoptosis(18,24). In the present study, BTX-A application did not 
result in a significant change to corneal parameters. It remains unclear 
whether BTX-A application to the orbicularis oculi muscles could be 
a useful adjuvant approach for controlling the progression of kerato-
conus. Corneal changes after the application of BTX-A in orbicularis 
oculi muscles, if there are any, take longer to be detected than earlier 
eyelid morphometric changes(18); our follow-up period may therefore 
not have been long enough to detect associated corneal changes 
in patients with keratoconus. Furthermore, keratoconic corneas may 
present structural alterations that respond differently from the corneas 
of patients with hemifacial spasm. 
We recognize potential limitations in this study. The number of 
BTX-A applications was limited, and the follow-up period was rela-
tively short. Future studies of keratoconus patients with a longer 
follow-up period and an increased number of BTX-A applications may 
help to elucidate whether BTX-A application in the orbicularis oculi 
muscle could be a valuable adjuvant treatment to help control the 
progression of keratoconus to some degree.
Keratoconus etiology and pathogenesis mechanisms remain 
unclear. The recent Global Consensus on Keratoconus and Ectatic Di -
seases(25) concluded that keratoconus was a multifactorial disease with 
genetic, biochemical, biomechanical, and environmental components. 
The panelists found that the most important objectives of nonsurgical 
treatment were to halt progression and bring about visual rehabilitation.
The past two decades, in particular, have seen exciting new de-
velopments that, for the first time, promise to alter the natural history 
of keratoconus favorably to benefit patients. Scientific interest in 
keratoconus is likely to remain high in the foreseeable future, to avoid 
iatrogenic ectasia, unmask subclinical disease, and expand the rapeutic 
options(26).
In conclusion, BTX-A administration to the orbicularis oculi muscles 
of keratoconus patients did not cause detectable changes in corneal 
parameters secondary to reduced eyelid muscular force during 18 
months of follow-up.
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Table 5. Comparison of Goldmann applanation tonometry measurements between the botulinum toxin-A injection and control groups
Parameter, mean (SD) Baseline 3 months 6 months 12 months 18 months
GAT, mmHg
Control 9.1 (2.3) 8.8 (2.5) 8.9 (2.7) 9.3 (3.0) 9.1 (1.8)
BTX-A 9.3 (2.2) 8.4 (2.5) 8.6 (2.5) 7.6 (2.4) 8.3 (3.1)
SD= standard deviation; GAT= Goldmann applanation tonometry; BTX-A= botulinum toxin-A.
